{"id":538774,"date":"2021-04-15T18:34:01","date_gmt":"2021-04-15T18:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=538774"},"modified":"2021-04-15T18:34:01","modified_gmt":"2021-04-15T18:34:01","slug":"aspergillosis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-pfizer-pulmocide-astellas-pharma-nektar-therapeutics-regeneron-pharmaceuticals-sanofi-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/aspergillosis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-pfizer-pulmocide-astellas-pharma-nektar-therapeutics-regeneron-pharmaceuticals-sanofi-and-others_538774.html","title":{"rendered":"Aspergillosis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Pfizer, Pulmocide, Astellas Pharma, Nektar Therapeutics, Regeneron Pharmaceuticals, Sanofi and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Aspergillosis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Pfizer, Pulmocide, Astellas Pharma, Nektar Therapeutics, Regeneron Pharmaceuticals, Sanofi and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Aspergillosis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Pfizer, Pulmocide, Astellas Pharma, Nektar Therapeutics, Regeneron Pharmaceuticals, Sanofi and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Aspergillosis Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Aspergillosis<\/strong> is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;<strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/aspergillosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Aspergillosis Pipeline<\/a> Insights, 2021,&rdquo;<\/strong>&nbsp;report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Aspergillosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get free sample page @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/aspergillosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/aspergillosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of Aspergillosis Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Pulmocide<\/li>\n<li>Astellas Pharma<\/li>\n<li>Nektar Therapeutics<\/li>\n<li>Pulmatrix<\/li>\n<li>F2G<\/li>\n<li>Pfizer<\/li>\n<li>Cellix Bio<\/li>\n<li>Regeneron Pharmaceuticals\/Sanofi<\/li>\n<li>Scynexis<\/li>\n<li>Matinas BioPharma<\/li>\n<li>TFF Pharmaceuticals<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get free sample page @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/aspergillosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/aspergillosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s report covers around 50+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase II and Phase II\/III)<\/li>\n<li>Mid-stage products (Phase II and Phase II\/III)<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/aspergillosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Aspergillosis Therapies<\/a><\/strong><strong>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>PC 945<\/li>\n<li>Itraconazole inhaled<\/li>\n<li>Isavuconazole<\/li>\n<li>Amphotericin B inhalation<\/li>\n<li>Olorofim<\/li>\n<li>Anidulafungin\/voriconazole<\/li>\n<li>CLX IFN 59<\/li>\n<li>Dupilumab<\/li>\n<li>Ibrexafungerp:<\/li>\n<li>MAT2203<\/li>\n<li>TFF VORI<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get free sample page @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/aspergillosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/aspergillosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Aspergillosis: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Aspergillosis &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">&bull; Aspergillosis companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">Aspergillosis Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Dupilumab: Regeneron Pharmaceuticals\/Sanofi<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Ibrexafungerp: Scynexis<\/p>\n<p style=\"text-align: justify;\">PC945: Pulmocide<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">TFF VORI: TFF Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Pre-clinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">MAT2203: Matinas BioPharma<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Aspergillosis Key Companies<\/p>\n<p style=\"text-align: justify;\">Aspergillosis Key Products<\/p>\n<p style=\"text-align: justify;\">Aspergillosis- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Aspergillosis- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Aspergillosis- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Aspergillosis Analyst Views<\/p>\n<p style=\"text-align: justify;\">Aspergillosis Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=aspergillosis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-pfizer-pulmocide-astellas-pharma-nektar-therapeutics-regeneron-pharmaceuticals-sanofi-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/aspergillosis-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/aspergillosis-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/aspergillosis-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=aspergillosis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-pfizer-pulmocide-astellas-pharma-nektar-therapeutics-regeneron-pharmaceuticals-sanofi-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aspergillosis Pipeline Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/aspergillosis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-pfizer-pulmocide-astellas-pharma-nektar-therapeutics-regeneron-pharmaceuticals-sanofi-and-others_538774.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-538774","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=538774"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538774\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=538774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=538774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=538774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}